Palbonix 125 mg (Generic Palbociclib) – Beacon Pharmaceuticals

Palbonix 125 mg is a generic formulation of Palbociclib — a CDK4/6 inhibitor — manufactured by Beacon Pharmaceuticals Ltd., Bangladesh’s largest dedicated oncology pharmaceutical company. Each capsule contains 125 mg of palbociclib, the same active molecule found in Ibrance® (Pfizer), and is dispensed under the Named Patient Program for patients requiring an affordable, quality-assured alternative.

Palbonix is also available in a 100 mg strength for patients requiring dose reduction. Palbociclib is always used in combination with hormone (endocrine) therapy — it is not approved as a standalone treatment.

HR-positive breast cancer cells rely on oestrogen signalling to drive a protein pair called cyclin D1-CDK4/6, which propels them through the cell division cycle. Palbociclib selectively inhibits CDK4 and CDK6, blocking cancer cells at the G1 checkpoint before they can replicate.

Palbociclib follows a 28-day cycle structure — understanding this pattern helps you anticipate blood test timing and expected symptoms.

• Days 1–14: Your white blood cell count, especially neutrophils, typically begins to fall — this is expected and closely monitored. A blood test is usually scheduled around day 14 of your first two treatment cycles.
• Days 15–21: Continue daily dosing through day 21. Mild fatigue or nausea may emerge. Blood counts typically reach their lowest point around this window before recovery begins.
• Days 22–28 (off period): A mandatory 7-day pause allows bone marrow and blood counts to recover before the next cycle starts. This off-period is built into the regimen for safety — do not skip it.

The most clinically significant effect of palbociclib is suppression of white blood cells (neutropenia), making frequent blood monitoring mandatory, particularly in the first two cycles.

Standard dose: 1 capsule (125 mg) once daily for 21 consecutive days, followed by 7 days off — a complete 28-day cycle. Taken together with your prescribed hormone therapy.

• 1
  Once daily for 21 days, then 7 days off — track the cycle carefully using a calendar; consistent tracking helps both you and your care team.
• 2
  Take with food — food improves absorption and reduces nausea. Avoid grapefruit and grapefruit juice entirely (CYP3A4 interaction).
• 3
  Swallow capsules whole with a full glass of water. Do not open, crush, or chew.
• 4
  If you miss a dose or vomit shortly after taking one, do not take an additional dose — resume at the next scheduled time.
• 5
  Storage: below 30°C, protected from moisture and light, out of reach of children.

• ♥
  Watch for fever closely, especially days 10–21 — neutrophil counts are typically lowest during this window. Any temperature of 38°C or higher needs immediate medical contact — treat it as a possible emergency, not something to wait out.
• ♥
  Help track the 28-day cycle — mark dosing days and the 7-day off period clearly on a calendar or in an app. Missing this schedule is a common and entirely avoidable error.
• ♥
  Support infection precautions — encourage hand hygiene, avoid crowded indoor spaces when counts are low, and ensure all scheduled blood tests are kept.